Serologicals says that Upstate Group, its wholly owned subsidiary, has expanded its Kinease FP product line to include each of the 80 individual kinases that have been validated in the assay
By offering either a fluorescein green tracer or 645nm FarRed tracer for reduced compound interference, there are a total of 160 new additions to its Kinease FP activity assays.
Kinease is the first non-radioactive kinase assay that preserves the relevance of enzyme kinetics with a substrate turnover of less than ten percent.
Upstate introduced the FarRed tracer in the spring of 2005 and, in keeping with its strategic goal of product enhancement and expansion, now offers the widest variety of kinase testing products available.
"This expanded capability is ideal for kinase profiling, secondary screening, HTS assays and substrate identification," said David Dodd, president and chief executive officer of Serologicals.
"Upstate is committed to fueling drug discovery research by carefully selecting kinases with important biological and therapeutic relevance".
Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market.
Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology.
Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, G-proteins and cytokines, Upstate's advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits, multiplex assays are used by thousands of customers worldwide, every day to accelerate improving human health.
